¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Medicamento con receta

Clorfenamina y codeína (codeine phosphate and chlorpheniramine maleate)

Datos oficiales de la FDA, no son consejos

Todo lo que aparece aquí viene de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA): la etiqueta del medicamento, el directorio NDC, Drugs@FDA, los informes de retiros y la lista de escasez. Cada dato indica su fuente y su fecha.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

En una emergencia, llame al 911. Si alguien pudo haber tomado demasiado de un medicamento, llame a la Línea de Ayuda para Envenenamientos (Poison Help): 1‑800‑222‑1222.

Clorfenamina y codeína: datos clave

Se usa para
En inglés, según la etiqueta: TUXARIN ER is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. (fuente)
Con receta o sin receta
Con receta (Rx)
Hay genérico
La FDA no indica genérico
Último retiro de la FDA
Ninguno registrado

Fuentes: etiqueta de la FDA (10 de enero de 2024); directorio NDC de la FDA (30 de octubre de 2026); informes de retiros de la FDA (27 de octubre de 2026). No es un consejo médico.

Respuestas rápidas

¿Para qué se usa Clorfenamina y codeína?
La etiqueta aprobada por la FDA (Tuxarin, Mainpointe Pharmaceuticals, 10 de enero de 2024) dice, en inglés: “TUXARIN ER is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. TUXARIN ER is a combination of codeine, an opioid agonist …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Cuáles son los efectos secundarios de Clorfenamina y codeína?
La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Tuxarin, Mainpointe Pharmaceuticals, 10 de enero de 2024) comienza así, en inglés: «The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, abuse, and misuse [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.3)] Life-threatening respiratory depression [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.9), Overdosage (10)] Ultra-rapid metabolism of codeine and other risk factors for life-threatening respiratory depression in children [see Warnings and Precautions (5.3)] Accidental …» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Qué interacciones tiene Clorfenamina y codeína?
La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Tuxarin, Mainpointe Pharmaceuticals, 10 de enero de 2024) comienza así, en inglés: «No specific drug interaction studies have been conducted with TUXARIN ER. Phenytoin: Avoid concomitant use; may increase phenytoin levels. (7.4) Serotonergic drugs: Concomitant use may result in serotonin syndrome. Discontinue if serotonin syndrome is suspected. (7.6) Muscle relaxants: Avoid concomitant use. (7.8) Diuretics: Codeine may reduce the efficacy of diuretics. Monitor for reduced effect. (7.9) Anticholinergic drugs: Concurrent use may cause paralytic ileus.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Clorfenamina y codeína tiene una advertencia en recuadro?
Sí. La etiqueta de la FDA de Tuxarin tiene una advertencia en recuadro, la advertencia más seria de la FDA. Léala en la etiqueta completa y pregunte a su farmacéutico.
¿Hay escasez de Clorfenamina y codeína?
La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 30 de octubre de 2026).
¿Se ha retirado del mercado Clorfenamina y codeína?
No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
¿Quién fabrica Clorfenamina y codeína?
1 empresa tiene productos con receta de Clorfenamina y codeína en el directorio NDC de la FDA, entre ellas Mainpointe Pharmaceuticals.

Para qué se usa Clorfenamina y codeína

Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.

TUXARIN ER is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. TUXARIN ER is a combination of codeine, an opioid agonist …

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Leer la etiqueta completa en DailyMed →

Etiqueta citada: la de la presentación más común (tablet, extended release, oral), Tuxarin, Mainpointe Pharmaceuticals; abarca 1 producto del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

Advertencia en recuadro

La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.

Esta etiqueta tiene una advertencia en recuadro. Leerla en la etiqueta completa →

Clorfenamina y codeína: lo que dice la advertencia en recuadro

Cita de la advertencia en recuadro (Boxed Warning) de la etiqueta aprobada por la FDA. Se muestra en inglés.

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTIAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTIAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPOID WITHDRAWAL SYNDROME See full prescribing information for complete boxed warning.

Leer más de esta sección

TUXARIN ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor closely for these behaviors and conditions. (5.1) Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or when used in patients at higher risk. (5.2) Accidental ingestion of TUXARIN ER, especially by children, can result in a fatal overdose of codeine. (5.2) Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. (5.3) TUXARIN ER is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. (4) Avoid the use of TUXARIN ER in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine. Ensure accuracy when prescribing, dispensing, and administering TUXARIN ER. Dosing errors can result in accidental overdose and death. (2.1, 5.6) The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. Avoid the use of TUXARIN ER in these patients. (5.4, 7.1, 7.2, 7.4) Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of TUXARIN ER in patients taking benzodiazepines, other CNS depressants, or alcohol. (5.9, 7.5) TUXARIN ER is not recommended for use in pregnant women. Prolonged use of TUXARIN ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If TUXARIN ER is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (5.15, 8.1) Addiction, Abuse, and Misuse TUXARIN ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Reserve TUXARIN ER for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made.

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Efectos secundarios de Clorfenamina y codeína

Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.

The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, abuse, and misuse [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.3)] Life-threatening respiratory depression [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.9), Overdosage (10)] Ultra-rapid metabolism of codeine and other risk factors for life-threatening respiratory depression in children [see Warnings and Precautions (5.3)] Accidental …

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Interacciones de Clorfenamina y codeína

Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.

No specific drug interaction studies have been conducted with TUXARIN ER. Phenytoin: Avoid concomitant use; may increase phenytoin levels. (7.4) Serotonergic drugs: Concomitant use may result in serotonin syndrome. Discontinue if serotonin syndrome is suspected. (7.6) Muscle relaxants: Avoid concomitant use. (7.8) Diuretics: Codeine may reduce the efficacy of diuretics. Monitor for reduced effect. (7.9) Anticholinergic drugs: Concurrent use may cause paralytic ileus.

Leer más de esta sección

(5.10, 7.10) 7.1 Inhibitors of CYP3A4 The concomitant use of TUXARIN ER with CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), or protease inhibitors (e.g., ritonavir), may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of TUXARIN ER is achieved [see Warnings and Precautions (5.8)]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels [see Clinical Pharmacology (12.3)], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to codeine. Avoid the use of TUXARIN ER while taking a CYP3A4 inhibitor. If concomitant use is necessary, monitor patients for respiratory depression and sedation at frequent intervals. 7.2 CYP3A4 Inducers The concomitant use of TUXARIN ER and CYP3A4 inducers, such as rifampin, carbamazepine, or phenytoin, can result in lower codeine levels, greater norcodeine levels, and less metabolism via 2D6 with resultant lower morphine levels [see Clinical Pharmacology (12.3)], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence [see Warnings and Precautions (5.8)]. After stopping a CYP3A4 inducer, as the effects of the inducer decline, codeine plasma concentrations may increase with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels [see Clinical Pharmacology (12.3)], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. Avoid the use of TUXARIN ER in patients who are taking CYP3A4 inducers. If concomitant use of a CYP3A4 inducer is necessary, follow the patient for reduced efficacy. 7.3 Phenytoin Adverse event reports in the literature suggest a possible drug interaction involving increased serum phenytoin levels and phenytoin toxicity when chlorpheniramine and phenytoin are co-administered. The exact mechanism for this interaction is not known, however it is believed that chlorpheniramine may inhibit the hepatic metabolism of phenytoin. Avoid the use of TUXARIN ER while taking phenytoin. 7.4 Inhibitors of CYP2D6 Codeine is metabolized by CYP2D6 to form morphine.

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Dosis de Clorfenamina y codeína

Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.

Adults 18 years of age and older: 1 tablet every 12 hours as needed, not to exceed 2 tablets in 24 hours. (2.2) Do not increase the dose or dosing frequency. (2.1) Prescribe for the shortest duration consistent with treatment goals. (2.3) Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology. (2.3) Reevaluate patient prior to refilling.

Leer más de esta sección

(2.3) 2.1 Important Dosage and Administration Instructions Administer TUXARIN ER by the oral route only. Advise patients not to increase the dose or dosing frequency of TUXARIN ER because serious adverse events such as respiratory depression may occur with overdosage [see Warnings and Precautions (5.2), Overdosage (10)]. The dosage of TUXARIN ER should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [see Dosage and Administration (2.3), Warnings and Precautions (5.5)]. 2.2 Recommended Dosage Adults 18 years of age and older: one tablet every 12 hours as needed, not to exceed 2 tablets in 24 hours. 2.3 Monitoring, Maintenance, and Discontinuation of Therapy Prescribe TUXARIN ER for the shortest duration that is consistent with individual patient treatment goals [see Warnings and Precautions (5.1)] Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy [see Warnings and Precautions (5.2)]. Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [see Warnings and Precautions (5.5)]. If a patient requires a refill, reevaluate the cause of the cough and assess the need for continued treatment with TUXARIN ER, the relative incidence of adverse reactions, and the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)]. Do not abruptly discontinue TUXARIN ER in a physically-dependent patient [see Drug Abuse and Dependence (9.3)]. When a patient who has been taking TUXARIN ER regularly and may be physically dependent no longer requires therapy with TUXARIN ER, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Leer la etiqueta completa en DailyMed →

Clorfenamina y codeína en el embarazo

Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.

Risk Summary TUXARIN ER is not recommended for use in pregnant women, including during or immediately prior to labor. Prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.15) and Clinical Considerations]. There are no available data with TUXARIN ER use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Leer más de esta sección

Published studies with codeine have reported inconsistent findings and have important methodological limitations (see Data). There are reports of respiratory depression when codeine is used during labor and delivery (see Clinical Considerations). Reproductive toxicity studies have not been conducted with TUXARIN ER; however, studies are available with individual active ingredients (see Data). In animal reproduction studies, codeine administered by the oral route to pregnant rats during the period of organogenesis increased resorptions and decreased fetal weights at a dose approximately 15 times the maximum recommended human dose (MRHD) in the presence of maternal toxicity (see Data). Chlorpheniramine administered by the oral route to mice throughout pregnancy was embryolethal at a dose approximately 9 times the MRHD and decreased postnatal survival when dosing was continued after parturition. Chlorpheniramine administered by the oral route to male and female rats prior to mating produced embryolethality at a dose approximately 9 times the MRHD (see Data). Based on the animal data, advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings and Precautions (5.15)]. Labor or Delivery Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Opioids, including TUXARIN ER, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions.

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Cuándo no se debe usar Clorfenamina y codeína

Cita de la sección «Contraindications» (contraindicaciones) de la etiqueta aprobada por la FDA. Se muestra en inglés.

TUXARIN ER is contraindicated for: All children younger than 12 years of age [see Warnings and Precautions (5.2, 5.3, 5.4), Use in Specific Populations (8.4)]. Postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Warnings and Precautions (5.2, 5.3)].

Leer más de esta sección

TUXARIN ER is also contraindicated in patients with: Significant respiratory depression [see Warnings and Precautions (5.2)] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.5)]. Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.10)]. Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days [see Warnings and Precautions (5.13), Drug Interactions (7.7)]. Hypersensitivity to codeine, chlorpheniramine, or any of the inactive ingredients in TUXARIN ER [see Adverse Reactions (6)]. Persons known to be hypersensitive to certain other opioids may exhibit cross-reactivity to codeine. Children younger than 12 years of age (4) Significant respiratory depression. (4) Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. (4) Known or suspected gastrointestinal obstruction, including paralytic ileus. (4) Concurrent use of monoamine oxidase inhibitor (MAOI) therapy or within the last 14 days. (4) Hypersensitivity to codeine or other opiates, chlorpheniramine, or any of the inactive ingredients in TUXARIN ER. (4)

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Leer la etiqueta completa en DailyMed →

Sobredosis de Clorfenamina y codeína

Cita de la sección «Overdosage» (sobredosis) de la etiqueta aprobada por la FDA. Se muestra en inglés. Si alguien pudo haber tomado demasiado, llame a Poison Help al 1-800-222-1222 (o al 911 en una emergencia).

Clinical Presentation Codeine Acute overdose with codeine is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, partial or complete airway obstruction, atypical snoring, hypotension, hypoglycemia, circulatory collapse, cardiac arrest, and death.

Leer más de esta sección

Codeine may cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see Clinical Pharmacology (12.2)]. Chlorpheniramine Signs and symptoms of chlorpheniramine overdosage may vary from central nervous system depression to stimulation. Central toxic effects are characterized by agitation, anxiety, delirium, disorientation, hallucinations, hyperactivity, sedation, and seizures. Severe overdosage may produce coma, medullary paralysis, and death. Peripheral toxicity includes hypertension, tachycardia, dysrhythmias, vasodilation, hyperpyrexia, mydriasis, urinary retention, and diminished gastrointestinal motility. Atropine-like signs and symptoms (dry mouth, fixed dilated pupils, flushing, tachycardia, hallucinations, gastrointestinal symptoms, convulsions, urinary retention, cardiac arrhythmias and coma) may be observed. Impaired secretion from sweat glands following toxic doses of drugs with anticholinergic side effects may predispose to hyperthermia. Toxic psychosis, a possible class effect from overdose of sedating antihistamines, has been reported. Treatment of Overdose Treatment of overdosage is driven by the overall clinical presentation, and consists of discontinuation of TUXARIN ER together with institution of appropriate therapy. Give primary attention to the reestablishment of adequate respiratory exchange through provision of a patent and protected airway and the institution of assisted or controlled ventilation. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. Gastric emptying may be useful in removing unabsorbed drug. The opioid antagonists, naloxone and nalmefene, are specific antidotes for respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to codeine overdose, administer an opioid antagonist. An antagonist should not be administered in the absence of clinically significant respiratory depression. Because the duration of opioid reversal is expected to be less than the duration of action of codeine in TUXARIN ER, carefully monitor the patient until spontaneous respiration is reliably reestablished. TUXARIN ER will continue to release codeine and add to the codeine load for 4 hours or longer following ingestion, necessitating prolonged monitoring.

— Etiqueta de la FDA: Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Presentaciones y vía de administración

Formas farmacéuticasTableta, de liberación prolongada
VíaOral
Productos con receta1 en el directorio NDC de la FDA
Nombres de marcaTuxarin

Empresas que tienen este medicamento

Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.

Historial de aprobación de la FDA

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
Solicitudes de marca y biológicas
SolicitudPatrocinadorAprobadaCambios aprobados después
NDA206323
TUXARIN ER
Mainpointe22 de junio de 2015 6, el último 10 de julio de 2026
2026: Etiquetado · 2023: Etiquetado · 2018: Etiquetado

Escasez

La lista de escasez de la FDA no incluye estos productos.

Base de datos de escasez de medicamentos de la FDA →

Retiros del mercado

No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.

Identificadores oficiales

RxCUI (RxNorm)1664543, 2099286
ID (SPL set ID) de la etiqueta citadaa7cfab67-6087-4ab4-b7cd-4f9295413180
Etiquetas de la FDA (SPL)1
Solicitudes de la FDANDA206323
Principios activos (FDA)CHLORPHENIRAMINE / CODEINE

Siguientes pasos

Fuentes

  1. Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Tuxarin, Mainpointe Pharmaceuticals, vigente desde el 10 de enero de 2024; vía openFDA, datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
  2. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
  3. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
  4. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 27 de octubre de 2026, consultados el 31 de octubre de 2026
  5. Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
  6. Nombre en español: RxNorm (Biblioteca Nacional de Medicina de EE. UU.) y Wikidata, vinculados por el identificador RxNorm (RxCUI) del principio activo, sin coincidencias aproximadas.

La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →

Informar un error → · Información para fabricantes de medicamentos